Beijing SL Pharmaceutical Lamivudine Receives Approval
This article was originally published in PharmAsia News
Executive Summary
Beijing SL Pharmaceutical has received a production license and new drug certification for its lamivudine capsule and lamivudine raw material for treating the hepatitis B virus. At present, TIPR Pharmaceutical's Daiding ranks top in China's lamivudine market with 57.75 percent, and GSK's Heptodin accounting for the remaining market share. According to estimates, hospitals in the country spend RMB 480 million on lamivudine and the drug will hit RMB 1 billion in revenue by 2010. Beijing SL believes that few companies have the capability to produce the drug, and supply still lags behind demand. It is thus optimistic about the potential of the product and will go into production soon. (Click here for more - Chinese Language)